A question worth carrying
Sermorelin, tesamorelin and CJC-1295 tell different stories
The names belong together. Their results need a little more space.
A folded paper passes across the library ledge.
What they share
All three copy growth hormone-releasing hormone, or GHRH. That signal prompts the pituitary, a small gland beneath the brain, to release growth hormone. The GHRH family review explains the connection.
Sermorelin copies the first 29 building blocks of the natural hormone. Tesamorelin uses the full 44-part chain with a chemical tail. CJC-1295 has changed building blocks. The form with DAC has an attachment that binds to a blood protein and helps it last longer.
The chemistry explains why these names come up together. It cannot tell us which one, if any, fits the concern that brought you here.
“Strongest” needs a definition
A longer-lasting signal, a larger hormone rise and a useful change in health are different results. Calling one peptide strongest skips the question of what anyone wanted it to do.
What the studies actually measured
The sermorelin study measured faster growth in children before puberty with growth hormone deficiency. It had no comparison group. It did not establish adult height gain.
The tesamorelin abdominal-fat trial involved adults with HIV and excess belly fat. The early CJC-1295 studies measured hormone responses in healthy adults. They were not three entries in the same contest.
Put the hoped-for benefit into words
Is the question about growth, deep abdominal fat or a hormone measurement? Each needs its own evidence. The height FAQ shows why a hormone rise cannot stand in for an extra inch of height.
What approval changes
Tesamorelin has an approved use and its own prescribing information. It is for excess abdominal fat in adults with HIV-associated lipodystrophy, a change in fat distribution. The label warns about blood sugar and fluid retention.
Sermorelin’s former approved products are no longer marketed. Compounded medicines today are not FDA-approved. Older studies reported flushing and injection-site pain; they cannot settle adult risk rates.
CJC-1295 has no approved medicine. FDA’s review of its forms describes safety concerns and limited human evidence. A lasting hormone response does not erase those gaps.
Bring the question to the person providing care
A clinician can connect the actual medicine and the intended benefit with your health history. These pages cannot make that choice. A shared receptor is a connection, not a personal prescription.